In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Bristol-Myers Squibb’s current price at $62.91 is substantially below its PERT-weighted fair value of $131.50, indicating significant upside potential with high confidence. Strong profitability (5/5) and growth (4/5) support valuation, while low leverage (1/5) highlights financial risks. Monte Carlo analysis shows high volatility but no downside scenarios below the current price, suggesting asymmetric risk-return.